Vaxcyte (PCVX) Change in Account Payables (2019 - 2026)

Vaxcyte (PCVX) has reported Change in Account Payables for 8 consecutive years, with -$269000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables rose 99.08% year-over-year to -$269000.0; the TTM figure through Mar 2026 stood at $48.8 million (up 19542.23% YoY), while the FY2025 annual figure was $19.9 million, down 42.44% from the prior year.
• Change in Account Payables fell to -$269000.0 in Q1 2026 per PCVX's latest filing, from $21.7 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $31.3 million in Q4 2024 and bottomed at -$29.2 million in Q1 2025.
• Historically, Change in Account Payables has averaged $4.0 million across 5 years, with a median of $2.7 million in 2022.
• Annual changes were most pronounced in 2024 — Change in Account Payables surged 1097.55% — and 2025, when it tumbled 614.16%.
• Vaxcyte's Change in Account Payables stood at $3.5 million in 2022, then jumped by 86.66% to $6.5 million in 2023, then soared by 383.24% to $31.3 million in 2024, then plunged by 30.8% to $21.7 million in 2025, then slumped by 101.24% to -$269000.0 in 2026.
• Business Quant data shows PCVX's Change in Account Payables at -$269000.0 in Q1 2026, $21.7 million in Q4 2025, and $17.9 million in Q3 2025.